Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in two upcoming investor conferences:
1. The Mizuho Neuro & Ophthalmology Summit 2025, where management will participate in a panel presentation on Wednesday, May 21, 2025, at 11:25 a.m. ET
2. The Jefferies Global Healthcare Conference, featuring a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET. This presentation will be webcast live and accessible through the company's investor relations website, with a replay available for 90 days following the event.
Collegium Pharmaceutical (Nasdaq: COLL) ha annunciato la sua partecipazione a due prossime conferenze per investitori:
1. Il Mizuho Neuro & Ophthalmology Summit 2025, durante il quale il management prenderà parte a una presentazione in panel mercoledì 21 maggio 2025 alle 11:25 ET.
2. La Jefferies Global Healthcare Conference, con una presentazione prevista per giovedì 5 giugno 2025 alle 13:25 ET. Questa presentazione sarà trasmessa in diretta streaming e sarà accessibile tramite il sito web delle relazioni con gli investitori dell’azienda, con una replica disponibile per 90 giorni dopo l’evento.
Collegium Pharmaceutical (Nasdaq: COLL) ha anunciado su participación en dos próximas conferencias para inversores:
1. La Cumbre Mizuho Neuro & Ophthalmology 2025, donde la dirección participará en una presentación en panel el miércoles 21 de mayo de 2025 a las 11:25 a.m. ET.
2. La Conferencia Global de Salud de Jefferies, con una presentación el jueves 5 de junio de 2025 a la 1:25 p.m. ET. Esta presentación será transmitida en vivo y estará disponible a través del sitio web de relaciones con inversores de la empresa, con una repetición accesible durante 90 días después del evento.
Collegium Pharmaceutical (나스닥: COLL)는 두 개의 예정된 투자자 컨퍼런스에 참여한다고 발표했습니다:
1. Mizuho Neuro & Ophthalmology Summit 2025로, 경영진이 2025년 5월 21일 수요일 오전 11시 25분(동부시간)에 패널 발표에 참여합니다.
2. Jefferies Global Healthcare Conference로, 2025년 6월 5일 목요일 오후 1시 25분(동부시간)에 발표가 예정되어 있습니다. 이 발표는 회사 투자자 관계 웹사이트를 통해 생중계되며, 행사 후 90일 동안 다시보기 서비스를 제공합니다.
Collegium Pharmaceutical (Nasdaq : COLL) a annoncé sa participation à deux prochaines conférences pour investisseurs :
1. Le Mizuho Neuro & Ophthalmology Summit 2025, où la direction participera à une présentation en panel le mercredi 21 mai 2025 à 11h25 ET.
2. La Jefferies Global Healthcare Conference, avec une présentation prévue le jeudi 5 juin 2025 à 13h25 ET. Cette présentation sera diffusée en direct via webcast et accessible sur le site des relations investisseurs de la société, avec un replay disponible pendant 90 jours après l'événement.
Collegium Pharmaceutical (Nasdaq: COLL) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt:
1. Der Mizuho Neuro & Ophthalmology Summit 2025, bei dem das Management am Mittwoch, den 21. Mai 2025, um 11:25 Uhr ET an einer Podiumsdiskussion teilnehmen wird.
2. Die Jefferies Global Healthcare Conference, mit einer Präsentation am Donnerstag, den 5. Juni 2025, um 13:25 Uhr ET. Diese Präsentation wird live per Webcast übertragen und ist über die Investor-Relations-Website des Unternehmens zugänglich, mit einer Wiederholung, die 90 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
Mizuho Neuro & Ophthalmology Summit 2025
Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET
Jefferies Global Healthcare Conference
Presentation: Thursday, June 5, 2025, at 1:25 p.m. ET
The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Media Contact:
Cheryl Wheeler
Head of Corporate Communications
communications@collegiumpharma.com
FAQ
When is Collegium Pharmaceutical (COLL) presenting at the Jefferies Global Healthcare Conference 2025?
How can I watch Collegium's (COLL) presentation at the Jefferies Healthcare Conference 2025?
When is Collegium (COLL) participating in the Mizuho Neuro & Ophthalmology Summit 2025?
Which investor conferences is Collegium Pharmaceutical (COLL) attending in 2025?
